NCT05380882 is a Phase 1 clinical trial of TQB2930 injection in Advanced Cancers, sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd..

What drugs are being tested in NCT05380882?

Interventions in NCT05380882: TQB2930 injection.

What condition does NCT05380882 study?

NCT05380882 studies Advanced Cancers.

Is NCT05380882 still recruiting?

NCT05380882 is currently status unknown. Last updated 18 May 2022.

Last reviewed 2022-05-18 · How we verify

NCT05380882

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase I Study of TQB2930 Injection in Patients With Advanced Cancers

Status unknown Phase 1 Last updated 18 May 2022

What this trial tests

Phase 1 trial testing TQB2930 injection in Advanced Cancers in 60 participants. Status unknown.

Timeline

1 May 2022

Primary endpoint
1 April 2023

1 December 2023

Quick facts

Lead sponsor	Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase	Phase 1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	60
Start date	1 May 2022
Primary completion	1 April 2023
Estimated completion	1 December 2023
Sites	1 location across China

Drugs / interventions tested

TQB2930 injection — full drug profile →

Conditions studied

Advanced Cancers — all drugs for Advanced Cancers →

Sponsor

Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. — full company profile →

Who can join

Adults 18 to 75, any sex, with Advanced Cancers. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Dose Limiting Toxicity (DLT)
Time frame: At the end of Cycle 1 (each cycle is 21 or 28 days)
DLT will be defined as toxicities that meet pre-defined severity criteria(according to the NCI CTCAE v5.0 toxicity assessment criteria), and assessed as having a suspected relationship to study drug that occurred from the first dose to the end of the first treatment cycle.
Maximum tolerated dose (MTD)
Time frame: At the end of Cycle 1 (each cycle is 21 or 28 days).
MTD was defined as the highest dose at which dose-limiting toxicity (DLT) occurred in less than 33% of patients.
Adverse events (AE) rate
Time frame: From date of the first dose until the date of 28 days after last dose or new anti-tumor treatment, whichever came first.
The occurrence and severity of all AEs

Sponsor's own description

TQB2930 is an anti-HER2 (Human Epidermal Growth Factor Receptor 2) bispecific antibody that can simultaneously bind two epitopes of HER2, leading to a dual HER2 signal blockage. This is a phase I study to evaluate the safety, tolerability and effectiveness of TQB2930 injection in subjects with advanced malignancies.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Biparatopic antibodies: therapeutic applications and prospects.
Niquille DL, Fitzgerald KM, Gera N. · · 2024 · cited 41× · PMID 38439551 · DOI 10.1080/19420862.2024.2310890
Immunotherapies against HER2-Positive Breast Cancer.
Duro-Sánchez S, Alonso MR, Arribas J. · · 2023 · cited 18× · PMID 36831412 · DOI 10.3390/cancers15041069
Clinical Progresses and Challenges of Bispecific Antibodies for the Treatment of Solid Tumors.
Gu Y, Zhao Q. · · 2024 · cited 16× · PMID 39172329 · DOI 10.1007/s40291-024-00734-w
Current Indications and Future Landscape of Bispecific Antibodies for the Treatment of Lung Cancer.
Arasanz H, Chocarro L, Fernández-Rubio L, Blanco E, et al · · 2023 · cited 6× · PMID 37373003 · DOI 10.3390/ijms24129855
Application and future prospects of bispecific antibodies in the treatment of non-small cell lung cancer.
Wen J, Cui W, Yin X, Chen Y, et al · · 2025 · cited 5× · PMID 40192238 · DOI 10.20892/j.issn.2095-3941.2024.0470

Verify or expand the search:

Other recruiting trials for Advanced Cancers

Currently open trials in the same condition.

NCT06001749 — Psilocybin in Cancer Pain Study · Phase 2 · recruiting
NCT03375983 — Plasmodium Immunotherapy for Advanced Cancers · Phase 1, PHASE2 · recruiting
NCT01375114 — The Effects of Ginseng on Cancer-Related Fatigue · Phase 1, PHASE2 · active not recruiting

Other Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. trials

Trials by the same sponsor.

NCT07052097 — Clinical Trial of TQC2938 Injection in Patients With Seasonal Allergic Rhinitis · Phase 2 · completed
NCT06929195 — Clinical Trial to Evaluate the Tolerance of TQB2210 Injection · Phase 1 · completed
NCT06542614 — Treatment of Moderate to Severe Plaque Psoriasis · Phase 2 · completed
NCT06451640 — A Extension Clinical Study of TQC2731 Injection in the Treatment of Chronic Sinusitis With Nasal Polyps · Phase 2 · completed
NCT06438783 — TQB2928 Injection Combined Anlotinib Hydrochloride Capsule in Recurrent/Metastatic Osteosarcoma and Other Solid Tumors · Phase 1 · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05380882 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Last refreshed: 18 May 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05380882.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing